A voluntary US Food and Drug Administration program intended to help manufacturers prevent product shortages will not survive the upcoming generic drug user fee reauthorization.
FDA and industry representatives agreed during a 22 April GDUFA III negotiating session “to not move forward with the Site...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?